Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARDS 2: Once-weekly insulin icodec vs once-daily insulin degludec in type 2 diabetes
jRCT2031200421Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2021
- Modality
- Peptides
01
Overview
Phase 3, randomised trial of insulin icodec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c at 26 weeks. Started Mar 2021; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031200421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200421.